Roche said it will run a new Phase 3 trial for the controversial Duchenne muscular dystrophy gene therapy Elevidys in another attempt to win approval for the therapy in Europe and other regions.

The

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844